BCA
BSTC

Berman Capital Advisors’s BioSpecifics Technologies Corp. BSTC Stock Holding History

Berman Capital Advisors’s Portfolio BSTC Stock Details BSTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-19
Closed -$1K – 1598
2019
Q3 		$1K Hold
19
– – ﹤0.01% 1415
2019
Q2 		$1K Hold
19
– – ﹤0.01% 1434
2019
Q1 		$1K Buy
+19
New +$1.26K ﹤0.01% 1314

Other funds holding BSTC

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Berman Capital Advisors's BSTC Position: Q4 2019 in Review

Berman Capital Advisors sold out of BioSpecifics Technologies Corp. (BSTC) in Q4 2019, closing a stake of 19 shares — an estimated $1K sold.

Berman Capital Advisors first reported a position in BSTC in Q1 2019 and held it in 3 quarters. The position peaked at $1K in Q3 2019. 112 funds tracked by Wall St. Rank hold BSTC as of Q4 2019.

  • Berman Capital Advisors reported no remaining BioSpecifics Technologies Corp. position as of Q4 2019 after selling out during the quarter.
  • Berman Capital Advisors sold 19 BioSpecifics Technologies Corp. shares in Q4 2019, an estimated $1K.
  • Berman Capital Advisors first reported a position in BioSpecifics Technologies Corp. in Q1 2019 and held it in 3 quarters.
  • Berman Capital Advisors's BioSpecifics Technologies Corp. position peaked at $1K in Q3 2019.
  • 112 funds tracked by Wall St. Rank held BioSpecifics Technologies Corp. as of Q4 2019.

Based on Berman Capital Advisors's 13F filing for Q4 2019, filed 14 Feb 2020.